Collegium Pharmaceutical (COLL) Scheduled to Post Quarterly Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL) is scheduled to release its earnings data after the market closes on Thursday, August 8th. Analysts expect Collegium Pharmaceutical to post earnings of $1.32 per share for the quarter. Collegium Pharmaceutical has set its FY 2024 guidance at EPS.Persons interested in registering for the company’s earnings conference call can do so using this link.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 EPS for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.04). The business had revenue of $144.92 million during the quarter, compared to analyst estimates of $147.04 million. Collegium Pharmaceutical had a net margin of 16.46% and a return on equity of 104.98%. On average, analysts expect Collegium Pharmaceutical to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $34.15 on Wednesday. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of 14.23 and a beta of 0.93. Collegium Pharmaceutical has a 52 week low of $20.95 and a 52 week high of $40.95. The company’s 50-day moving average price is $32.96 and its 200 day moving average price is $34.81. The company has a current ratio of 1.21, a quick ratio of 1.14 and a debt-to-equity ratio of 1.98.

Analysts Set New Price Targets

A number of brokerages recently commented on COLL. Needham & Company LLC reissued a “hold” rating on shares of Collegium Pharmaceutical in a research note on Tuesday, July 30th. HC Wainwright raised shares of Collegium Pharmaceutical from a “neutral” rating to a “buy” rating and set a $47.00 price target on the stock in a research note on Tuesday, July 30th. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 1st. Piper Sandler cut shares of Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 price target on the stock. in a research note on Friday, May 10th. Finally, Jefferies Financial Group raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and raised their target price for the stock from $41.00 to $44.00 in a research report on Friday, June 7th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Insider Activity

In other news, EVP Scott Dreyer sold 56,807 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $33.98, for a total transaction of $1,930,301.86. Following the sale, the executive vice president now owns 105,902 shares in the company, valued at $3,598,549.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Scott Dreyer sold 56,807 shares of Collegium Pharmaceutical stock in a transaction on Friday, May 24th. The shares were sold at an average price of $33.98, for a total value of $1,930,301.86. Following the completion of the sale, the executive vice president now owns 105,902 shares in the company, valued at $3,598,549.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Garen G. Bohlin sold 28,985 shares of Collegium Pharmaceutical stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $32.30, for a total transaction of $936,215.50. Following the completion of the transaction, the director now directly owns 44,775 shares of the company’s stock, valued at approximately $1,446,232.50. The disclosure for this sale can be found here. Insiders have sold 105,502 shares of company stock worth $3,540,796 over the last 90 days. Company insiders own 3.98% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.